Randomized Multicenter Phase II Trial of Two Different Schedules of Irinotecan Combined with Capecitabine as First-Line Treatment in Metastatic Colorectal Carcinoma

Ignazio Carreca, Antonio Lambiase, Luigi Mariani, Antonio Iannelli, Antonio Lambiase, Antonio Lambiase, Luigi Bonaglia, Antonio Cassata, Salvatore Artale, Maria Di Bartolomeo, Graziella Pinotti, Ignazio Carreca, Roberto Buzzoni, Sergio Frustaci, Ermina Ferrario, Andrea Bonetti, Elena Beretta, Guido Biasco, Emilio Bajetta, Giovanni MariniDiego Cortinovis

Risultato della ricerca: Articlepeer review

129 Citazioni (Scopus)

Abstract

BACKGROUND. The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC). METHODS. A total of 140 patients received capecitabine at a dose of 1250 mg/m(2) twice daily on Days 2-15 and irinotecan at a dose of either 300 mg/m(2) on Day 1 (Arm A) or 150 mg/m(2) on Days 1 and 8 (Arm 13) every 3 weeks. During the course of the study, enrollment was continued using lower doses of capecitabine (1000 mg/m(2) twice daily) and irinotecan (Arm A: 240 mg/m(2); Arm 13: 120 mg/m(2)) to improve the safety profile of the combinations. RESULTS. Efficacy was evaluable in 134 patients (68 in Arm A, 66 in Arm B). Objective responses were observed in 46% of the patients (8% complete response [CR]), including 47% in Arm A (9% CR; 38% partial response [PR]) and 44% in Arm B (8% CR; 36% PR). The median progression-free survival was 8.3 months in Arm A and 7.6 months in Arm B. Among the first 52 patients treated with the higher doses, the most frequent Grade 3-4 adverse event was diarrhea (27%). The lower doses adopted in the subsequent 88 patients led to better diarrhea control, particularly in Arm A, and significant reductions in the incidence of all-grade hand-foot syndrome and abdominal pain. CONCLUSIONS. The capecitabine and irinotecan combination was a highly active first-line therapy in metastatic CRC. An acceptable safety profile was observed after dose reduction, particularly when irinotecan was administered on 1 day. (C) 2003 American Cancer Society.
Lingua originaleEnglish
pagine (da-a)279-287
Numero di pagine9
RivistaCancer
Volume100
Stato di pubblicazionePublished - 2004

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'Randomized Multicenter Phase II Trial of Two Different Schedules of Irinotecan Combined with Capecitabine as First-Line Treatment in Metastatic Colorectal Carcinoma'. Insieme formano una fingerprint unica.

Cita questo